ER、PR、P53在子宫内膜癌中的表达及对预后的影响

目的 评估ER、PR、P53在子宫内膜癌(endometrial cancer,EC)中的表达及对预后的影响.方法 分析我院2005年1月-2011年3月173例子宫内膜癌患者的ER(estrogen receptor)、PR(progestin receptor)、P53(P53 protein)与子宫内膜癌的病理及预后关系.结果 ER在子宫内膜癌的不同类型、病理要素间表达有统计学差异,ER阳性的生存率(100％),显著高于ER阴性生存率(88.3％)(P＜0.05),ER表达＞75％生存率(100％)与＜75％生存率(95.3％)无统计学差异(P＞0.05).PR在子宫内膜癌的不同类型、病理要素间表达有统计学差异,PR阳性与阴性的生存率、＞75％与＜75％的生存率有统计学差异(P＜0.05).P53在两型子宫内膜癌中表达有统计学差异,在病理要素间表达无统计学差异,阳性与阴性的生存率无统计学差异(P＞0.05),表达＞75％与＜75％生存率有统计学差异(P＜0.05).结论 ER、PR和P53与子宫内膜癌类型、病理要素相关,是影响预后、判断良恶性的指标.

Expressions of estrogen receptor, progestin receptor and P53 in endometrial carcinoma and their effect on its prognosis

Objective To assess the expressions of estrogen receptor(ER),progestin receptor(PR),and P53 in endometrial cancer and their effect on its prognosis.Methods Correlation of expressions of ER,PR and P53 in 173 endometrial cancer patients admitted to our hospital from January 2005 to March 2011 with the pathology and prognosis of endometrial cancer was analyzed.Results No significant difference was observed in expression of ER in different types and pathology of endometrial cancer.The survival rate of ER-positive patients was significantly higher than that of ER-negative patients(100% vs 88.3%,P<0.05).No significant difference was found in ER-positive patients with a survival rate >75% or <75%(100% vs 95.3%,P>0.05).The expression of PR was significantly different in different types and pathology of endometrial cancer.The survival rate of PR-positive and negative patients with a survival rate >75% or <75% was significantly different(P<0.05).The expression of P53 was significantly different in different types of endometrial cancer(P<0.05) with no significant difference in pathology of endometrial carcinoma and in survival rate of P53-positive or negative patients.The survival rate of PR positive or negative patients with a survival rate >75% or <75% was significantly different(P<0.05).Conclusion ER,PR and P53 are correlated with the types of endometrial cancer and can thus be used as indications for its prognosis and for the judgment of whether it is malignant or benign.